Feasibility of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Light-Chain Cardiac Amyloidosis
Xuezhu Wang,Yubo Guo,Yajuan Gao,Chao Ren,Zhenghai Huang,Bowei Liu,Xiao Li,Long Chang,Kaini Shen,Haiyan Ding,Hui Zhang,Zhuang Tian,Marcus Hacker,Shuyang Zhang,Yining Wang,Jian Li,Xiang Li,Li Huo
DOI: https://doi.org/10.1016/j.jcmg.2022.06.004
IF: 16.051
2022-01-01
JACC Cardiovascular Imaging
Abstract:BACKGROUND Systemic amyloid light chain (AL) amyloidosis is the most common type of amyloidosis, leading to cardiomyocyte necrosis and interstitial fibrosis. Gallium-68-labeled fibroblast activation protein inhibitor 04 (Ga-68-FAPI-04) has recently been introduced for imaging fibroblast activation in cardiac diseases. To date, cardiac fibroblast and cardiac amyloidosis (CA) phenotype activities have not been mapped. OBJECTIVES The aim of this study was to evaluate the feasibility of Ga-68-FAPI-04 positron emission tomography (PET)/computed tomography (CT) in assessing AL CA. METHODS Thirty consecutive patients (mean age: 59.1 +/- 7.7 years; 20 men, 10 women) with biopsy-proven AL amyloidosis were enrolled prospectively (including 27 with AL CA and 3 without AL CA). All patients underwent Ga-68-FAPI-04 PET/CT (107.4 +/- 26.5 MBq). Global standardized uptake values and left ventricular (LV) molecular volume were calculated in correlation to echocardiography (n = 30), cardiac magnetic resonance (n = 18), and clinical biomarkers. Subsequently, the patients were categorized as having patchy (PET-patchy), extensive (PET-extensive), and negative (PET-negative) patterns. RESULTS Of all patients, 80% (24 of 30) showed increased LV uptake (PET-patchy [n = 4] vs PET-extensive [n = 20]), whereas 6 patients did not show visible myocardial uptake. Standardized uptake value ratio and LV molecular volume were significantly higher in the PET-extensive than the PET-patchy group (2.79 mL +/- 1.22 mL vs 1.53 mL +/- 0.66 mL [P = 0.045] and 198.3 mL +/- 59.97 mL vs 127.8 mL +/- 25.82 [P = 0.005], respectively). Additionally, Ga-68-FAPI-04 uptake was significantly correlated with clinical biomarkers (Mayo stage and N-terminal pro-brain natriuretic peptide), interventricular septal thickness, left ventricular ejection fraction (LVEF), LV end-systolic volume, extracellular volume, and LV global strain (P < 0.05). CONCLUSIONS Ga-68-FAPI-04 PET/CT is feasible in detecting myocardial fibroblast activation in patients with AL CA in correlation with myocardial remodeling. It might provide complementary information on cardiac molecular characterization and staging of disease. (J Am Coll Cardiol Img 2022;15:1960-1970) (c) 2022 by the American College of Cardiology Foundation.